Long acting GLP-1 receptor agonist (injectable)
Exenatide extended release injection
EXENER_SC
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Dapagliflozin | MD -0.20 (-1.21 to 0.92) | 0.43 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.07 (-1.28 to -0.85) | 0.72 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.15 (-2.39 to 0.40) | 0.51 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.26 (-1.08 to 0.62) | 0.21 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.78 (-1.73 to 0.57) | 0.45 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.70 (-1.61 to 0.43) | 0.60 |
| Type 2 diabetes (adults) | HbA1c change | weeks 64 to 130 (target week 104) | Insulin glargine | MD -0.20 (-1.19 to 0.86) | 0.63 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -0.98 (-2.01 to -0.03) | 0.66 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -2.44 (-6.57 to 2.02) | 0.53 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -6.24 (-11.77 to 0.36) | 0.75 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -5.57 (-11.64 to 2.55) | 0.86 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -1.48 (-6.42 to 3.84) | 0.60 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 64 to 130 (target week 104) | Insulin glargine | MD -4.46 (-9.44 to 0.98) | 0.86 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 2.42 (0.82 to 5.33) | 0.29 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 5.67 (1.26 to 18.42) | 0.95 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.05 (0.00 to 0.94) | 0.77 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.52 (0.00 to 37.23) | 0.72 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.43 (0.43 to 4.59) | 0.54 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.93 (0.37 to 2.28) | 0.53 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -2.34 (-3.88 to -0.69) | 0.60 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -0.80 (-6.75 to 5.49) | 0.37 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -2.16 (-5.41 to 1.05) | 0.32 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -2.63 (-8.57 to 3.41) | 0.55 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 3.04 (0.93 to 10.24) | 0.88 |
| Type 2 diabetes (adults) | All cause mortality | longest follow-up | Placebo | HR 0.86 (0.56 to 1.37) | 0.54 |
| Type 2 diabetes (adults) | Three point MACE | longest follow-up | Placebo | HR 0.91 (0.53 to 1.54) | 0.41 |
| Type 2 diabetes (adults) | Hospitalization for heart failure | longest follow-up | Placebo | HR 0.94 (0.54 to 1.76) | 0.58 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 0.71 (-1.13 to 2.54) | 0.70 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.97 (0.78 to 1.20) | 0.50 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.33 (0.83 to 2.08) | 0.52 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.83 (1.32 to 2.58) | 0.49 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.93 (1.30 to 2.92) | 0.51 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.43 (1.09 to 1.87) | 0.48 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.61 (1.12 to 2.34) | 0.44 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 1.49 (0.60 to 3.52) | 0.48 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 1.01 (0.14 to 7.48) | 0.34 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 0.59 (0.04 to 7.55) | 0.57 |
| Type 2 diabetes (adults) | Any cancer | longest follow-up | Placebo | HR 0.74 (0.15 to 3.13) | 0.75 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -6.59 (-16.61 to 3.91) | 0.74 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -3.94 (-11.82 to 4.09) | 0.36 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 10.40 (1.61 to 97.45) | 0.64 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 7.91 (0.54 to 209) | 0.52 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.90 (0.06 to 13.18) | 0.60 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.66 (0.09 to 3.89) | 0.80 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.47 (0.69 to 11.03) | 0.59 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.63 (0.35 to 26.83) | 0.63 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.97 (0.17 to 5.34) | 0.71 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.81 (0.18 to 22.39) | 0.51 |
| Children and adolescents with obesity | Percent BMI change | weeks 40 to 104 (target week 68) | Placebo | MD -5.29 (-14.11 to 4.11) | 0.74 |
| Children and adolescents with obesity | Serious adverse events | longest follow-up | Placebo | HR 2.80 (0.11 to 95.22) | 0.27 |
| Children and adolescents with obesity | Nausea | longest follow-up | Placebo | HR 2.07 (0.53 to 7.60) | 0.52 |
| Children and adolescents with obesity | Vomiting | longest follow-up | Placebo | HR 6.91 (1.40 to 41.55) | 0.31 |
| Children and adolescents with obesity | Diarrhea | longest follow-up | Placebo | HR 1.96 (0.49 to 7.96) | 0.28 |
| Children and adolescents with obesity | Constipation | longest follow-up | Placebo | HR 0.98 (0.20 to 4.91) | 0.74 |
| Children and adolescents with type 2 diabetes | Serious adverse events | longest follow-up | Placebo | HR 0.86 (0.08 to 11.52) | 0.53 |
| Children and adolescents with type 2 diabetes | Nausea | longest follow-up | Placebo | HR 1.65 (0.20 to 17.96) | 0.44 |
| Children and adolescents with type 2 diabetes | Vomiting | longest follow-up | Placebo | HR 4.36 (0.30 to 131) | 0.31 |
| Children and adolescents with type 2 diabetes | Diarrhea | longest follow-up | Placebo | HR 1.99 (0.28 to 21.63) | 0.34 |
| Type 1 diabetes | HbA1c change | weeks 12 to 40 (target week 26) | Placebo | MD -0.27 (-1.18 to 0.65) | 0.55 |
| Type 1 diabetes | Total daily insulin dose change | weeks 12 to 40 (target week 26) | Placebo | MD -0.04 (-0.24 to 0.17) | 0.48 |
| Type 1 diabetes | Serious adverse events | longest follow-up | Placebo | HR 0.68 (0.01 to 54.01) | 0.55 |
| Polycystic ovary syndrome | Nausea | longest follow-up | Standard care or no added treatment | HR 1.12 (0.26 to 4.83) | 0.70 |
| Polycystic ovary syndrome | Diarrhea | longest follow-up | Standard care or no added treatment | HR 0.78 (0.19 to 3.13) | 0.54 |
| Alcohol use disorder | Serious adverse events | longest follow-up | Placebo | HR 1.34 (0.32 to 5.22) | 0.33 |
| Alcohol use disorder | Nausea | longest follow-up | Placebo | HR 2.66 (0.63 to 10.28) | 0.44 |
| Alcohol use disorder | Vomiting | longest follow-up | Placebo | HR 3.10 (0.69 to 13.04) | 0.08 |
Trials
- Exenatide-PD3A Randomised, Double Blind, Parallel Group, Placebo Controlled, Phase 3 Trial of Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease2020 · 194 randomized · 96 weeks
- NCT04029272Study on the Effect of Metformin vs Metformin Combined With GLP-1 RA (Exenatide) on Overweight/Obese Patients With Polycystic Ovary Syndrome (PCOS)2019 · 50 randomized · 12 weeks
- EXALTDoes Glucagon-like Peptide (GLP-1) Receptor Agonist Stimulation Reduce Alcohol Intake in Patients With Alcohol Dependence?2017 · 127 randomized · 26 weeks
- EXENDAA 24 Week Monocentric Prospective Randomized, Placebo-controlled Trial to Evaluate Efficacy of Combination of Exenatide and Dapagliflozin Compared to Dapagliflozin and Placebo and Its Effects on Hepatic, Myocardial and Pancreatic Fat Distribution in Patients With Uncontrolled Type 2 Diabetes Mellitus.2017 · 30 randomized · 24 weeks
- NCT01554618A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study to Assess the Safety and Efficacy of Exenatide Once Weekly in Adolescents With Type 2 Diabetes2016 · 83 randomized · 52 weeks
- NCT02496611Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity2015 · 66 randomized · 52 weeks
- NCT02887625Efficacy and Durability of Glucagon Like Peptide 1 Receptor Agonists (GLP-1 RA)/Thiazolidinedione Versus Basal Bolus Insulin Therapy in Poorly Controlled Type 2 Diabetic Patients (T2DM) Patients on Sulfonylurea Plus Metformin2015 · 251 randomized · 156.54 weeks
- RebuildEffects on Re-endothelialisation With Bydureon Treatment Add on to Insulin Versus Insulin Alone, Both in Combination With Metformin in Type 2 Diabetic Subjects2015 · 38 randomized · 12 weeks
- NCT02229396A 28-week, Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study With a 24-week Extension Phase Followed by a 52-week Extension Phase to Evaluate the Efficacy and Safety of Simultaneous Administration of Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg Compared to Exenatide Once Weekly 2 mg Alone and Dapagliflozin Once Daily 10 mg Alone in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin2014 · 695 randomized · 104 weeks
- DapalostA 24-week, Single Centre, Randomized, Parallel-group, Double-blind, Placebo Controlled Phase II Study With an Optional 28-week Open-label Extension to Evaluate the Efficacy on Body Weight of Dapagliflozin 10 mg Once Daily in Combination With Exenatide 2 mg Once Weekly in Obese Non-diabetic Subjects.2014 · 50 randomized · 24 weeks
- NCT02229383A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Once Weekly Exenatide Therapy Added to Titrated Basal Insulin Glargine Compared to Placebo Added to Titrated Basal Insulin Glargine in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Glargine With or Without Metformin2014 · 464 randomized · 28 weeks
- NCT02288273A Randomized Double-blind, Parallel-group Study to Evaluate the Effect of BYDUREON Compared With Placebo on 24-hour Glucose Control in Metformin-treated Patients With Type 2 Diabetes2014 · 117 randomized · 10 weeks
- SUSTAIN™ 3Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3 - vs. QW GLP-1)2013 · 813 randomized · 56 weeks
- DURATION-NEO-2A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus2013 · 365 randomized · 28 weeks
- NCT01144338Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus.2010 · 14,752 randomized
- NCT01029886Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes and Inadequate Glycemic Control Treated With Lifestyle Modification and Oral Antidiabetic Medications2010 · 912 randomized · 26 weeks
- NCT01003184Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulphonylurea2009 · 222 randomized · 26 weeks
- NCT00917267A Comparator-Controlled Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control (HbA1c) and Safety in Asian Subjects With Type 2 Diabetes Mellitus Managed With Oral Antidiabetic Medications2009 · 681 randomized · 26 weeks
- NCT00935532Parallel Group Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus Treated With Oral Antidiabetic(s)2009 · 427 randomized · 26 weeks
- NCT00894322A Two-Cohort, Single- and Repeat Dose Study to Examine the Pharmacokinetics, Tolerability, and Safety of Ready to Use Exenatide Once Weekly in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus2009 · 35 randomized · 12 weeks
- NCT00877890A Randomized, Open-Label, Parallel-Group, Comparator-Controlled, Multicenter Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus2009 · 254 randomized · 24 weeks
- NCT00676338Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes2008 · 820 randomized · 26 weeks
- NCT00637273A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Long-Acting Release(Once Weekly) to Those of Sitagliptin and a Thiazolidinedione in Subjects With Type 2 Diabetes Mellitus Treated With Metformin2008 · 514 randomized · 26 weeks
- NCT00641056Efficacy of Once-Weekly Exenatide Long-Acting Release and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea2008 · 467 randomized · 84 weeks
- NCT00612794Multiple-Dose Study to Examine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2148568 Long-Acting Release in Japanese Patients With Type 2 Diabetes Mellitus2007 · 30 randomized · 10 weeks